Estrogen Therapy Linked to Lower Alzheimer's Risk in Women

Recent research has shed new light on the potential benefits of estrogen-only hormone therapy for women in later life, particularly in regards to dementia and Alzheimer's disease. A large-scale study involving over 21,000 participants has found a significant link between hormone therapy use and a reduced risk of dementia diagnosis. According to the study, women who used estrogen-only hormone therapy had 39% lower odds of being diagnosed with dementia, compared to those who did not undergo hormone therapy.

The study also discovered a correlation between hormone therapy use and fewer signs of Alzheimer's disease in the brains of participants at autopsy. Specifically, hormone therapy users showed 35% lower odds of Alzheimer's-related brain changes, including the presence of amyloid plaques and tau tangles. Additionally, biomarker tests revealed lower levels of amyloid buildup among hormone therapy users, suggesting a potential protective effect against the development of Alzheimer's disease.

The findings of this study offer promising insights into the potential benefits of estrogen-only hormone therapy for women in later life, particularly in terms of dementia and Alzheimer's disease prevention. While further research is needed to confirm these results and explore their implications, the study's conclusions highlight the importance of continued investigation into the complex relationships between hormone therapy, brain health, and age-related cognitive decline.